

Daniel L Gustafson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862300/publications.pdf>

Version: 2024-02-01

65
papers

2,187
citations

293460

24
h-index

263392

45
g-index

65
all docs

65
docs citations

65
times ranked

3961
citing authors

#	ARTICLE	IF	CITATIONS
1	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 662-676.	3.2	38
2	Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs. <i>American Journal of Veterinary Research</i> , 2022, 83, 86-94.	0.3	10
3	Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3943-3961.	2.9	3
4	Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses. <i>Journal of Equine Veterinary Science</i> , 2022, 113, 103933.	0.4	11
5	PLASMA CONCENTRATION AND PHARMACODYNAMICS OF INTRAMUSCULAR ADMINISTRATION OF ALFAXALONE IN INDIAN PEA FOWL (PAVO CRISTATUS). <i>Journal of Zoo and Wildlife Medicine</i> , 2022, 53, 108-115.	0.3	2
6	Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 294-305.	1.3	14
7	Predicting chemosensitivity using drug perturbed gene dynamics. <i>BMC Bioinformatics</i> , 2021, 22, 15.	1.2	1
8	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). <i>Clinical Cancer Research</i> , 2021, 27, 2435-2441.	3.2	46
9	Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. <i>Clinical Cancer Research</i> , 2021, 27, 3005-3016.	3.2	26
10	Evaluation of Intra-Articular Amikacin Administration in an Equine Non-inflammatory Joint Model to Identify Effective Bactericidal Concentrations While Minimizing Cytotoxicity. <i>Frontiers in Veterinary Science</i> , 2021, 8, 676774.	0.9	5
11	Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 699-712.	1.1	0
12	Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 331-342.	1.3	4
13	Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (<i>Cavia</i>) Tj ETQq1 1 0,784314 µgBT /Ov 0,6		
14	Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. <i>Communications Biology</i> , 2021, 4, 1178.	2.0	10
15	Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease. <i>Journal of Feline Medicine and Surgery</i> , 2020, 22, 376-383.	0.6	11
16	Drug dose and drug choice: Optimizing medical therapy for veterinary cancer. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 143-151.	0.8	5
17	Dose-Escalation and Pharmacokinetic Study Following a Single Dose of Oxaliplatin in Cancer-Bearing Dogs. <i>Journal of the American Animal Hospital Association</i> , 2020, 56, 206-214.	0.5	0
18	Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2020, 44, 552.	0.6	4

#	ARTICLE	IF	CITATIONS
19	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1598-1612.	1.9	19
20	<p>Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib</p>. <i>Oncolytic Virotherapy</i> , 2020, Volume 9, 17-29.	6.0	1
21	Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. <i>Cancer Research</i> , 2020, 80, 2689-2702.	0.4	24
22	Cancer Cells Upregulate NRF2 Signaling to Adapt to Autophagy Inhibition. <i>Developmental Cell</i> , 2019, 50, 690-703.e6.	3.1	74
23	The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 588-592.	0.6	7
24	Drug Design Targeting T-Cell Factor-Driven Epithelialâ€“Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10182-10203.	2.9	12
25	A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies. <i>BMC Medical Genomics</i> , 2019, 12, 87.	0.7	10
26	Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1460-1471.	1.9	24
27	Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. <i>Molecular Pharmacology</i> , 2019, 96, 36-46.	1.0	22
28	Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2019, 47, 257-268.	1.7	25
29	The fecal microbiome and serum concentrations of indoxyl sulfate and pâ€resol sulfate in cats with chronic kidney disease. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 662-669.	0.6	37
30	Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 147-154.	0.8	12
31	SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4506-4506.	0.8	26
32	Hydroxychloroquine Sensitivity in Human and Canine Cancer Cell Line Panels Reveals Potential Genetic Signatures of Autophagyâ€“Dependence and Druggable Targets. <i>FASEB Journal</i> , 2019, 33, 509.3.	0.2	0
33	Targeting the ErbB/MAPK Signaling Cascade in Canine Bladder Cancer Cell Lines. <i>FASEB Journal</i> , 2019, 33, 509.2.	0.2	0
34	Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 447-459.	1.3	67
35	Canine sarcomas as a surrogate for the human disease. , 2018, 188, 80-96.		53
36	In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 1951-1957.	0.6	11

#	ARTICLE	IF	CITATIONS
37	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 5398-5407.	0.4	20
38	Assessment of Modeling Techniques and Feature Selection for Predicting Drug Response from Gene Expression Data for Cytotoxic Anticancer Agents. <i>FASEB Journal</i> , 2018, 32, 566.5.	0.2	0
39	Vinca Alkaloid Pharmacokinetics in the Context of a Physiologically-Based Murine Model. <i>FASEB Journal</i> , 2018, 32, 834.3.	0.2	0
40	Assessment of absorption of transdermal ondansetron in normal research cats. <i>Journal of Feline Medicine and Surgery</i> , 2017, 19, 1245-1248.	0.6	4
41	Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. <i>Journal of Feline Medicine and Surgery</i> , 2017, 19, 998-1006.	0.6	23
42	Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 282-293.	1.3	56
43	A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain. <i>European Journal of Pharmacology</i> , 2016, 784, 1-14.	1.7	4
44	Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. <i>BMC Bioinformatics</i> , 2016, 17, 93.	1.2	31
45	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5.	5.8	108
46	Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at 20°C and room temperature. <i>Veterinary Dermatology</i> , 2015, 26, 228.	0.4	9
47	Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats. <i>Veterinary Anaesthesia and Analgesia</i> , 2015, 42, 472-483.	0.3	13
48	STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious. <i>Cancer Research</i> , 2014, 74, 2579-2590.	0.4	155
49	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. <i>Autophagy</i> , 2014, 10, 1415-1425.	4.3	149
50	Autophagy and Cancer Therapy. <i>Molecular Pharmacology</i> , 2014, 85, 830-838.	1.0	268
51	Pharmacokinetics of sustained-release analgesics in mice. <i>Journal of the American Association for Laboratory Animal Science</i> , 2014, 53, 478-84.	0.6	47
52	Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 437-449.	0.8	15
53	Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 157-176.	0.8	40
54	Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4149-4162.	3.2	61

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 349-360.	1.1	42
56	A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man. <i>Clinical Cancer Research</i> , 2007, 13, 2768-2776.	3.2	70
57	Continuous Low-Dose Oral Chemotherapy for Adjuvant Therapy of Splenic Hemangiosarcoma in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2007, 21, 764-769.	0.6	119
58	Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 179-188.	1.1	45
59	Tissue Distribution and Metabolism of the Tyrosine Kinase Inhibitor ZD6474 (Zactima) in Tumor-Bearing Nude Mice following Oral Dosing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 872-880.	1.3	25
60	P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 248-254.	1.1	32
61	Pharmacokinetics of combined doxorubicin and paclitaxel in mice. <i>Cancer Letters</i> , 2005, 220, 161-169.	3.2	66
62	Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 159-166.	1.1	57
63	Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1079-1086.	1.3	19
64	Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1488-1501.	1.6	84
65	Expression of human O6-methyl guanine methyl transferase (MGMT) in post replication repair (PRR) deficient CHO-UV-1 cells: Compensation for hypersensitivity to methylating and ethylating agents but not to mitomycin C. <i>Somatic Cell and Molecular Genetics</i> , 1997, 23, 9-17.	0.7	2